Want to see ALDX full AI Analyst Report?
Top Page
Aldeyra Therapeutics
(NASDAQ:ALDX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-3.23% Downside)
Action:Reiterated
Date:08/07/26
The score is held down primarily by weak financial performance (no revenue, recurring losses, and persistent cash burn with worsened TTM outflows) and bearish technical signals (price below key moving averages and negative MACD). Valuation is difficult to assess due to negative earnings and no dividend yield data, while corporate events provide only a small positive offset.
Positive Factors
Targeted RASP platform
Aldeyra’s RASP-focused small‑molecule platform targets inflammatory drivers across ocular and immune-mediated diseases. A mechanism-based approach with a lead candidate (reproxalap) supports potential multi-indication utility and durable clinical value if trials succeed, aiding long-term commercialization optionality.
Negative Factors
No revenue base
Aldeyra remains pre-revenue with no product sales, meaning the business depends entirely on external financing and clinical milestones. Lack of commercial revenue prevents internal cash generation, increases dilution risk, and extends the timeline to durable profitability and margin sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted RASP platform
Aldeyra’s RASP-focused small‑molecule platform targets inflammatory drivers across ocular and immune-mediated diseases. A mechanism-based approach with a lead candidate (reproxalap) supports potential multi-indication utility and durable clinical value if trials succeed, aiding long-term commercialization optionality.
Read all positive factors
Aldeyra Therapeutics (ALDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$93.51M
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)2.74
Revenue GrowthN/A
EPS Growth54.84%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,326,420
10 Day Avg. Volume1,276,042
30 Day Avg. Volume1,746,381
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside29.03% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$1.25M
Aldeyra Therapeutics Business Overview & Revenue Model
Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinica...
How the Company Makes Money
null...
Aldeyra Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -66.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -21.37M | -31.69M | -53.68M | -35.21M | -60.07M | -55.77M |
| Net Income | -23.05M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
Balance Sheet | ||||||
| Total Assets | 47.54M | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Cash, Cash Equivalents and Short-Term Investments | 45.09M | 70.04M | 101.15M | 142.82M | 174.30M | 229.79M |
| Total Debt | 143.45K | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M |
| Total Liabilities | 9.66M | 27.81M | 33.60M | 28.53M | 30.28M | 27.40M |
| Stockholders Equity | 37.89M | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
Cash Flow | ||||||
| Free Cash Flow | -22.04M | -33.35M | -43.21M | -30.33M | -56.65M | -42.56M |
| Operating Cash Flow | -22.02M | -33.35M | -43.21M | -30.33M | -56.64M | -42.56M |
| Investing Cash Flow | 40.98M | 47.74M | -44.92M | 30.00M | -29.95M | -7.81K |
| Financing Cash Flow | -15.11M | 1.12M | -171.42K | -1.27M | 1.22M | 194.50M |
Aldeyra Therapeutics Technical Analysis
Neutral
1.55
Price Trends
1.76
Negative
1.72
Negative
3.14
Negative
Market Momentum
-0.05
Negative
46.35
Neutral
64.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Neutral. The current price of 1.55 is above the 20-day moving average (MA) of 1.54, below the 50-day MA of 1.76, and below the 200-day MA of 3.14, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 46.35 is Neutral, neither overbought nor oversold. The STOCH value of 64.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALDX.
Aldeyra Therapeutics Risk Analysis
Aldeyra Therapeutics disclosed 89 risk factors in its most recent earnings report. Aldeyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aldeyra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $1.04B | -9.42 | -89.38% | ― | ― | -108.75% | |
52 Neutral | $402.39M | -9.72 | 21.48% | ― | ― | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.40B | 9.54 | -109.40% | ― | ― | ― | |
48 Neutral | $406.79M | -6.76 | 72.64% | ― | 51.98% | 17.68% | |
45 Neutral | $93.51M | -4.03 | -53.14% | ― | ― | 54.84% | |
44 Neutral | $281.84M | -1.27 | -242.28% | ― | ― | 21.31% |
* Healthcare Sector Average
ALDX
Aldeyra Therapeutics
1.56
-4.30
-73.38%
OMER
Omeros
18.22
13.99
330.73%
GALT
Galectin Therapeutics
4.15
-0.10
-2.35%
FHTX
Foghorn Therapeutics
6.69
1.68
33.53%
CADL
Candel Therapeutics
13.28
7.46
128.18%
NMRA
Neumora Therapeutics, Inc.
1.56
-0.20
-11.36%
Aldeyra Therapeutics Corporate Events
Business Operations and Strategy
Aldeyra Therapeutics Leases New Concord Headquarters Space
Positive
Jul 30, 2026
On July 28, 2026, Aldeyra Therapeutics executed a lease agreement with Bradford Street, L.L.C. for approximately 4,067 square feet of office space at 23 Bradford Street in Concord, Massachusetts. The lease term runs from September 1, 2026 through ...
Executive/Board ChangesShareholder Meetings
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
Positive
Jun 10, 2026
On June 9, 2026, following its annual meeting of stockholders, Aldeyra Therapeutics appointed veteran biotech executive Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, determining that she meets SEC and Nasdaq indep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.